Earnings Per Share
EPS (Diluted)
Vertex Pharmaceuticals EPS (Diluted) decreased by 13.4% to $4.02 in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 61.4%, from $2.49 to $4.02. Over 3 years (FY 2021 to FY 2025), EPS (Diluted) shows an upward trend with a 19.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementIncome Statement
SectionEarnings Per Share
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026
How to read this metric
A narrowing gap between basic and diluted EPS suggests a lower risk of future dilution for existing shareholders.
Detailed definition
Diluted earnings per share measures a company's profit per share if all convertible securities, such as stock options, w...
Peer comparison
Standardized across all publicly traded companies to ensure that earnings are not overstated by ignoring potential share issuance.
Metric ID:
eps_dilutedHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.26 | $3.28 | $2.98 | $2.96 | $3.13 | $3.59 | $3.14 | $2.69 | $3.52 | $3.97 | $3.71 | $4.21 | -$13.92 | $4.01 | $2.49 | $3.99 | $4.20 | $4.64 | $4.02 |
| QoQ Change | — | >999% | -9.1% | -0.7% | +5.7% | +14.7% | -12.5% | -14.3% | +30.9% | +12.8% | -6.5% | +13.5% | -430.6% | +128.8% | -37.9% | +60.2% | +5.3% | +10.5% | -13.4% |
| YoY Change | — | — | — | — | >999% | +9.5% | +5.4% | -9.1% | +12.5% | +10.6% | +18.2% | +56.5% | -495.5% | +1.0% | -40.9% | +128.7% | +4.7% | — | +61.4% |
Range-$13.92 – $4.64
CAGR+83.8%
Avg YoY Growth+61.9%
Median YoY Growth+10.0%
EPS (Diluted) at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's eps (diluted)?
- Vertex Pharmaceuticals (VRTX) reported eps (diluted) of $4.02 in Q1 2026.
- How has Vertex Pharmaceuticals's eps (diluted) changed year-over-year?
- Vertex Pharmaceuticals's eps (diluted) increased by 61.4% year-over-year, from $2.49 to $4.02.
- What is the long-term trend for Vertex Pharmaceuticals's eps (diluted)?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's eps (diluted) has grown at a 19.4% compound annual growth rate (CAGR), from $9.01 to $15.32.
- What does eps (diluted) mean?
- The profit per share calculated as if all possible stock options and convertible bonds were turned into actual shares.